ABSTRACT
Schisandra chinensis fructus is the dried ripe fruit of S. chinensis from magnoliaceae, produced mainly in the three provinces in the northeast of China. This research systematically summarized the active constituent and pharmacological activity of S. chinensis fructus in recent years, and predicted the Q-marker of S. chinensis fructus in terms of component specificity, constituent validity, component measurability and component absorbed into blood based on the concept of the Q-marker of traditional Chinese medicine. The result suggested the component of lignans in diphenyl cyclooctene as the Q-marker of S. chinensis fructus to conduct the qualitative and quantitative analysis, which provides the scientific basis for establishing and improving the quality evaluation standard of S. chinensis fructus.
ABSTRACT
Because of the high morbidity and mortality rate,cardio-cerebrovascular diseases,including cerebral embolism, cerebral hemorrhage,cerebral vasospasm and myocardial infarction,have become main diseases threatening human health. Tradition-al chinese medicine(TCM)holds that the basic pathogenesis is Qi imbalances,which could be improved by benefiting Qi and promot-ing blood circulation. The compatibility of Radix astragali and Radix salviae miltiorrhiae are particularly suitable for treating the car-dio-cerebrovascular system diseases by improving Qi deficiency and blood stasis. This paper focuses on the application of Radix astrag-ali,Radix s. miltiorrhiae and their compatibility for treating the cardio-cerebrovascular system diseases. Moreover,our research would offer valuable references for the development of new drugs related to the treatment of cardio-cerebrovascular system diseases.
ABSTRACT
The article provides the references for R&D direction of Chinese materia medica (CMM) by searching and sorting the clinical approval of CMM in China. The overall analysis on CMM includes the total amounts, register classifications, indications, declared periods, formulations of approved herbal medicines, and potential reasons of their regularities. The annual approval amounts during 2010-2015 are obviously decreased in the past 6 years. Approved medicines (83.75%) are compound recipes that belong to the sixth class in register classifications. Involving indications, the total amounts of approved medicines from respiratory system, digestive system, cardio-cerebrovascular system, gynecology, and skeletal musculature system are accounted for 70.03% of total number. The calculated average declared period is 27.36 months, while the applications of endocrine, nutrition, metabolism disease, and cancer system have much longer declared periods than the others. Most formulations of approved medicines are solid oral preparations such as tablets, capsules, granules, and it displays a big difference in formulations between different therapeutic domains. Overall, the registration approval analysis reflects to a certain extent that now is the difficult time of CMM research and development as well as approvals, the new drug R&D should pay more attention on its clinical value.